Sinoway Industrial Co., Ltd.

Eptifibatide 188627-80-7 Eptifibatide 188627-80-7

Eptifibatide 188627-80-7
Related Products
  • NanoActive alpha lipoic acid (ALA) 1077-28-7

    1.Basic information of NanoActive alpha lipoic acidProduct Name: NanoActive alpha lipoic acid (ALA)Other Names: NanoActive THIOOCTIC ACIDAppearance: yellow, viscous and transparent liquidTest Method: ...

  • NanoActive Astaxanthin 472-61-7

    1.Basic information of NanoActive AstaxanthinProduct Name: NanoActive AstaxanthinOther Names: NanoActive AstaAppearance: reddish to dark red, viscous and transparent liquidTest Method: HPLCCAS NO.: 47...

  • NanoActive Curcumin 458-37-7

    1.Basic information of NanoActive CurcuminProduct Name: NanoActive CurcuminOther Names: NanoActive turmeric extractAppearance: yellow, viscous and transparent liquidTest Method: HPLCCAS NO.: 458-37-7S...

Basic information of Eptifibatide:

Name

Eptifibatide

CAS NO.

188627-80-7

Molecular Formula

C35H49N11O9S2

Molecular Weight

831.96

Grade Standard

Medicine grade  / 99% min / FDA / DMF

Package Size

1kg/bag; 5kg/tin; 25kg/drum

Storage:

Keep in a well-closed container, protected from light and stored at a temperature of 2 to 8


Use of Eptifibatide:

Eptifibatide is an antiplatelet agent of glycoprotein IIb / IIIa inhibitors. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the Southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of arginine-glycine-aspartate-mimetic and reversibly binds to platelets. The half-life of eptifibatide is short. This drug is the third inhibitor of GPIIb / IIIa, which has been widely found after the specific antibodies abciximab and non-peptide tirofiban entered the global market.

Indications
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).
The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.
The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.

Related ANTI-CANCER drug:
1. Cytarabine (CAS #147-94-4)
2. Methotrexate oral.Injection grade (CAS #59-05-2)
3. Paclitaxel(CAS:33069-62-4)
4. Doxorubicin Hydrochloride/CAS:25316-40-9
5. Vinblastine sulfate (CAS # 143-67-9)
6. Vincristine Sulfate (CAS #2068-78-2)
7. Vinorelbine Ditartrate (CAS #125317-39-7)
8. Gemcitabine hydrochloride (CAS#122111-03-9)
9. Mesylate-AZD9291 (CAS #1421373-66-1)

  • Solifenacin succinate 242478-38-2
    Basic information of Solifenacin succinate :NameSolifenacin succinateAlias1-azabicyclo[2.2.2]octan-8-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate butanedioic acid;vesicare;solifenacin s... Solifenacin succinate 242478-38-2
  • Apremilast 608141-41-9
    Basic information of ApremilastNameApremilastAliasApremilast (CC-10004)CAS NO.608141-41-9Molecular Formula C22H24N2O7SMolecular Weight 460.51Quality Standard99% minGrade StandardMedicine gradePackage ... Apremilast 608141-41-9
  • Hydrocortisone Acetate 50-03-3
    Basic informationProduct Name: Hydrocortisone AcetateMolecular Formula : C23H32O6Molecular Weight: 404.5CAS No.: 50-03-3Appearance: White crystalline powderSpecifications:EP8; EP6/USP37UsagesEczema, itchy... Hydrocortisone Acetate 50-03-3
  • Gliclazide 21187-98-4
    Basic information of Gliclazide :NameGliclazideAlias1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea ;1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)-ure ;1-(hexahydrocyclopenta(c... Gliclazide 21187-98-4

MORE_DETAIL Eptifibatide 188627-80-7

Basic information of Eptifibatide:

Name

Eptifibatide

CAS NO.

188627-80-7

Molecular Formula

C35H49N11O9S2

Molecular Weight

831.96

Grade Standard

Medicine grade  / 99% min / FDA / DMF

Package Size

1kg/bag; 5kg/tin; 25kg/drum

Storage:

Keep in a well-closed container, protected from light and stored at a temperature of 2 to 8


Use of Eptifibatide:

Eptifibatide is an antiplatelet agent of glycoprotein IIb / IIIa inhibitors. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the Southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of arginine-glycine-aspartate-mimetic and reversibly binds to platelets. The half-life of eptifibatide is short. This drug is the third inhibitor of GPIIb / IIIa, which has been widely found after the specific antibodies abciximab and non-peptide tirofiban entered the global market.

Indications
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).
The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.
The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.

Related ANTI-CANCER drug:
1. Cytarabine (CAS #147-94-4)
2. Methotrexate oral.Injection grade (CAS #59-05-2)
3. Paclitaxel(CAS:33069-62-4)
4. Doxorubicin Hydrochloride/CAS:25316-40-9
5. Vinblastine sulfate (CAS # 143-67-9)
6. Vincristine Sulfate (CAS #2068-78-2)
7. Vinorelbine Ditartrate (CAS #125317-39-7)
8. Gemcitabine hydrochloride (CAS#122111-03-9)
9. Mesylate-AZD9291 (CAS #1421373-66-1)
Leave a Message Email Us

We will contact you within 24 hours.

  • TEL:+86-0592-5853819
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//